KEROS THERAPEUTICS IN

Keros Therapeutics Announces Updated Time of Presentation at 2024 Cantor Global Healthcare Conference

12 9月 2024 07:00:00 条件 Nasdaq GlobeNewswire

Keros Therapeutics Announces Update on Enrollment in the Phase 2 TROPOS Trial

03 9月 2024 07:00:00 条件 Nasdaq GlobeNewswire

Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences

28 8月 2024 07:00:00 条件 Nasdaq GlobeNewswire

Keros Therapeutics Reports Second Quarter 2024 Financial Results

07 8月 2024 15:01:00 条件 Nasdaq GlobeNewswire

Keros Therapeutics Announces Leadership Updates

17 6月 2024 15:01:02 条件 Nasdaq GlobeNewswire

Keros Therapeutics Presents Clinical Data from its Elritercept (KER-050) Program at the 29th Annual Hybrid Congress of the European Hematology Association

17 6月 2024 05:00:00 条件 Nasdaq GlobeNewswire

Keros Therapeutics to Host a Corporate Update Conference Call and Webcast

04 6月 2024 07:00:00 条件 Nasdaq GlobeNewswire

Keros Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference

03 6月 2024 07:00:00 条件 Nasdaq GlobeNewswire

Keros Therapeutics Appoints Jean-Jacques Bienaimé to its Board of Directors

28 5月 2024 15:01:00 条件 Nasdaq GlobeNewswire

Keros Therapeutics to Present at the 29th Annual Congress of the European Hematology Association

14 5月 2024 09:00:00 条件 Nasdaq GlobeNewswire

Keros Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results

08 5月 2024 07:00:00 条件 Nasdaq GlobeNewswire

Keros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050 in Lower-Risk Myelodysplastic Syndromes

14 3月 2024 07:00:00 条件 Nasdaq GlobeNewswire

Keros Therapeutics to Present at Leerink Partners 2024 Global Biopharma Conference

05 3月 2024 07:00:00 条件 Nasdaq GlobeNewswire

Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

28 2月 2024 15:01:00 条件 Nasdaq GlobeNewswire

Keros Therapeutics To Present at Pulmonary Vascular Research Institute 2024 Annual Congress

29 1月 2024 07:00:00 条件 Nasdaq GlobeNewswire

Keros Therapeutics Announces Closing of Upsized Public Offering of Common Stock

09 1月 2024 07:00:00 条件 Nasdaq GlobeNewswire

Keros Therapeutics Announces Pricing of Upsized Public Offering of Common Stock

03 1月 2024 20:29:25 条件 Nasdaq GlobeNewswire

Keros Therapeutics Announces Proposed Public Offering of Common Stock

03 1月 2024 15:05:39 条件 Nasdaq GlobeNewswire

Keros Therapeutics to Develop KER-065 for the Treatment of Obesity

03 1月 2024 07:00:00 条件 Nasdaq GlobeNewswire

Keros Therapeutics Presents Clinical Data from its KER-050 Program at the 65th American Society of Hematology Annual Meeting and Exposition

11 12月 2023 05:00:00 条件 Nasdaq GlobeNewswire